← Back to Search

Capmatinib for Non-Small Cell Lung Cancer (Geometry-N Trial)

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed NSCLC stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2)
Participant must have either MET exon 14 mutations and/or high level MET amplification
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from time of surgery and at 24, 36, and 60 months
Awards & highlights

Geometry-N Trial Summary

This trial will test if adding the drug capmatinib to surgery, chemotherapy, and radiation can improve outcomes for people with early- to mid-stage non-small cell lung cancer that has MET mutations or high MET amplification.

Who is the study for?
This trial is for adults with early-stage Non-Small Cell Lung Cancer (NSCLC) stages IB-IIIA, specifically those with MET exon 14 mutations or high MET amplification. Candidates must be eligible for surgery and have no brain metastasis, prior cancer treatments within 3 years, lung conditions like pneumonitis, previous treatment with MET inhibitors, or major surgeries within the last month.Check my eligibility
What is being tested?
The study tests if capmatinib can improve patient outcomes when given before (neoadjuvant) and after (adjuvant) standard treatments such as surgery, chemotherapy, and radiation in NSCLC patients who are positive for certain genetic changes related to their cancer.See study design
What are the potential side effects?
Capmatinib may cause side effects including nausea, vomiting, increased liver enzymes which could indicate liver damage; swelling due to fluid retention; fatigue; difficulty breathing; and potential harm to an unborn baby if taken during pregnancy.

Geometry-N Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lung cancer is at a specific stage and has been confirmed by a tissue test.
Select...
My cancer has MET exon 14 mutations or high MET amplification.

Geometry-N Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from time of surgery and at 24, 36, and 60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and from time of surgery and at 24, 36, and 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major pathological response (MPR) rate based on local review
Secondary outcome measures
Complete pathologic response (pCR) rate based on central and local review
Disease free survival rate (DFS) from start of adjuvant therapy
Number of adverse events and serious adverse events as assessed by CTCAE criteria
+1 more

Geometry-N Trial Design

2Treatment groups
Experimental Treatment
Group I: Cohort BExperimental Treatment1 Intervention
Participants with NSCLC with high level MET amplification will take 400 mg tablet orally twice per day
Group II: Cohort AExperimental Treatment1 Intervention
Participants with NSCLC with MET exon 14 skipping mutations, irrespective of MET gene copy number (GCN) will take 400 mg tablet orally twice per day

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,866 Previous Clinical Trials
4,199,322 Total Patients Enrolled

Media Library

capmatinib Clinical Trial Eligibility Overview. Trial Name: NCT04926831 — Phase 2
Non-Small Cell Lung Cancer Clinical Trial 2023: capmatinib Highlights & Side Effects. Trial Name: NCT04926831 — Phase 2
~2 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top